Missed our May webinar? Efe Sumer, Senior Investment Associate at the Massachusetts Life Sciences Center (MLSC), spoke about their Impact Catalyst Fund, a critical MLSC resource designed to assist early-stage companies innovating in high disease burden areas as they pursue valuable opportunities to scale.
The deadline to apply for the Impact Catalyst Fund is June 12. Learn more about the program structure in our summary below.
The Impact Catalyst Fund is a non-dilutive funding program that offers up to $250,000 to seed-stage or first financing round-stage companies. This program prioritizes high-risk translational research in areas historically lacking investment proportional to disease burden, where innovation has the potential to transform patient outcomes. Focus areas can include medical devices & diagnostic tools, health equity solutions, psychiatric diseases & pain management therapies and microbiome & antibiotic innovations.
Interested companies must provide a dilutive match via letters of intent from investors, along with a Certificate of Good Standing from the state.
How can applicants stand out? According to Efe, companies that have already begun raising capital but need additional support to reach their next milestone are in the program’s “sweet spot.”
Many startups find they have raised an initial seed round and made progress, but need additional capital before pursuing a larger financing round. However, existing investors may be reluctant to participate further because they invested at a higher-risk stage and do not want their ownership diluted.
This is where the Impact Catalyst Fund can be especially valuable. Companies in a seed extension phase that are seeking additional capital to advance toward key milestones may be strong candidates for the program.
The diligence process for Impact Catalyst is extensive. Once the application period closes, MLSC conducts an initial program fit review. Companies that appear particularly promising then enter a deeper diligence phase, which typically runs through September or October.
During this process, MLSC speaks with prospective investors and shares diligence findings with parties interested in joining a company’s financing round. This thorough review can help attract additional investors by providing third-party validation of a company’s potential.
By the time award decisions are made in the fall, MLSC generally has a strong understanding of which investors are likely to participate in each selected company’s financing round.
Not every startup is ready for the Impact Catalyst Fund. Fortunately, MLSC offers several programs designed for earlier stages of company development.
One such program is Mass NextGen, which serves as a stepping stone for companies that are still establishing themselves and working toward raising their first institutional round of funding. The year-long program provides up to $100,000 in non-dilutive funding along with executive coaching, educational programming, and a curriculum designed to prepare companies for institutional fundraising.
In addition to Impact Catalyst and Mass NextGen, MLSC offers a variety of programs that support academic-industry partnerships, workforce growth, and tax incentives for life sciences companies. You can explore the full list of MLSC programs on their website.
Again, a reminder that the MLSC Impact Catalyst Fund is accepting applications through June 12: Apply now!
MFN regularly hosts webinars featuring investors, ecosystem leaders, and startup experts. To stay up to date about future events, funding opportunities, and founder resources, consider becoming an MFN member!
